Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus.
This study investigates the effects of troglitazone, an insulin sensitizer, on the clinical manifestation of coronary vasospastic angina pectoris in patients with diabetes mellitus. Troglitazone reduces frequency of angina pectoris and improves endothelial function.
Murakami
T
T
Department of Cardiology, Fukui Cardiovascular Center, Shimbo, Japan. fcc7@lilac.ocn.ne jp
Mizuno
S
S
Ohsato
K
K
Moriuchi
I
I
Arai
Y
Y
Nio
Y
Y
Kaku
B
B
Takahashi
Y
Y
Ohnaka
M
M
D000788:Angina Pectoris, Variant / Q000188:drug therapy*; D002839:Chromans / Q000627:therapeutic use*; D003925:Diabetic Angiopathies / Q000188:drug therapy*; D004730:Endothelium, Vascular / Q000187:drug effects; D006801:Humans; D007333:Insulin Resistance; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones; D013997:Time Factors; D000077288:Troglitazone; D014665:Vasodilator Agents / Q000627:therapeutic use*
D002839:Chromans; D013844:Thiazoles; D045162:Thiazolidinediones; D014665:Vasodilator Agents; D000077288:Troglitazone